« Equity and Loan Financing | Main | Eurostar grant »
Wednesday
Jan082014

FP7 Grant

MinervaX announces that the NeoStrep consortium, consisting of Lund University (Sweden), MinervaX ApS (Denmark), CiToxLAB A/S (Denmark), and BioKinetic Europe Ltd. (UK), has been awarded EUR 6 million in funding under the European Commission FP7 Programme HEALTH, for the development of a novel innovative Group B Streptococcal Vaccine candidate, owned by MinervaX.

Press release